Ignite Creation Date:
2026-03-26 @ 3:17 PM
Ignite Modification Date:
2026-04-06 @ 2:14 AM
Study NCT ID:
NCT07421856
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-02-19
First Post:
2025-12-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.
Sponsor:
Hebei Senlang Biotechnology Inc., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
S103-101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None